{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50","upperLimit":"59","value":"55"},{"groupId":"OG001","lowerLimit":"47","upperLimit":"55","value":"51"}]}],"title":"Received less than 10 Infusions of Remdesivir due to Discharge"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"2","value":"1"}]}],"title":"Received less than 10 Infusions of Remdesivir due to Death"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"70","value":"66"},{"groupId":"OG001","lowerLimit":"55","upperLimit":"64","value":"59"}]}],"title":"Received less than 14 doses of Baricitinib/Placebo due to Discharge"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"1","value":"0"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"3","value":"1"}]}],"title":"Received less than 14 doses of Baricitinib/Placebo due to Death"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"4","value":"2"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"3","value":"2"}]}],"title":"Had Any Infusions of Remdesivir Halted or Slowed"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13","upperLimit":"20","value":"16"},{"groupId":"OG001","lowerLimit":"14","upperLimit":"21","value":"18"}]}],"title":"Had Any Oral Doses of Baricitinib/Placebo Modified"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"27","value":"23"},{"groupId":"OG001","lowerLimit":"23","upperLimit":"31","value":"27"}]}],"title":"Missed Any Maintenance Dose of Remdesivir"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26","upperLimit":"34","value":"30"},{"groupId":"OG001","lowerLimit":"30","upperLimit":"38","value":"34"}]}],"title":"Missed Any Oral Dose of Baricitinib/Placebo"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"5","value":"3"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"6","value":"4"}]}],"title":"Terminated Early Prior to Completing 10 Infusions of Remdesivir"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"6","value":"4"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"7","value":"5"}]}],"title":"Terminated Early Prior to Completing 14 doses of Baricitinib/Placebo"}],"denoms":[{"counts":[{"groupId":"OG000","value":"515"},{"groupId":"OG001","value":"518"}],"units":"Participants"}],"description":"Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses of Remdesivir, or in the 14 doses of Baricitinib/placebo.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"NUMBER","populationDescription":"The intent-to-treat (ITT) population includes all participants who were randomized","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 14","title":"Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics","type":"SECONDARY","unitOfMeasure":"percentage of participants"}